NovoCure Limited 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2026-10-31
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about the broad US market.
Directly affected
- NVCR NovoCure-10.7% 11d
Named in this report.
Indirectly affected
- DIA SPDR Dow Jones Industrial Average ETF+0.3% 13d
SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story.
- QQQ Invesco QQQ-9.8% 30d
Invesco QQQ: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that NovoCure belongs to, so it often moves with news about it.
- SYK Stryker+16.7% 30d
Stryker is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- MMM 3M+15.1% 30d
3M is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- BSX Boston Scientific+3.8% 30d
Boston Scientific is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- BDX Becton, Dickinson and+19.7% 30d
Becton, Dickinson and is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- MDLN Medline+9.3% 30d
Medline is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NVCR | +9.63% | +7.65% | base | +0.42% | +2.40% | +11.19% | +3.16% |
| DIA | +1.17% | +1.48% | base | +0.44% | +0.00% | +3.10% | -0.47% |
| QQQ | +3.12% | +5.08% | base | -1.30% | -0.76% | +0.17% | -5.59% |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | +0.17% |
| SYK | +5.10% | +4.38% | base | +5.34% | +6.53% | +16.59% | +14.97% |
| MMM | -0.88% | -0.89% | base | +2.34% | +1.58% | +11.32% | +7.71% |
| BSX | +8.65% | +1.02% | base | +5.62% | +3.65% | +9.15% | +6.31% |
| BDX | -0.73% | -1.34% | base | +0.39% | +0.20% | +5.67% | +7.90% |
| MDLN | +4.92% | +0.90% | base | +4.80% | +6.26% | +25.81% | +23.96% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
NovoCure Limited 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2026-10-31 Seeking Alpha
Source: Seeking Alpha
This story
| Company | When | Move | Status |
|---|---|---|---|
| BDX | that day | +0.39% | final price |
| BDX | the next day | +0.20% | final price |
| BDX | two days later | +5.67% | final price |
| BDX | three days later | +7.90% | final price |
| BDX | three days earlier | -1.34% | final price |
| BDX | five days earlier | -0.73% | final price |
| BSX | that day | +5.62% | final price |
| BSX | the next day | +3.65% | final price |
| BSX | two days later | +9.15% | final price |
| BSX | three days later | +6.31% | final price |
| BSX | three days earlier | +1.02% | final price |
| BSX | five days earlier | +8.65% | final price |
| DIA | that day | +0.44% | final price |
| DIA | the next day | 0.00% | final price |
| DIA | two days later | +3.10% | final price |
| DIA | three days later | -0.47% | final price |
| DIA | three days earlier | +1.48% | final price |
| DIA | five days earlier | +1.17% | final price |
| MDLN | that day | +4.80% | final price |
| MDLN | the next day | +6.26% | final price |
| MDLN | two days later | +25.81% | final price |
| MDLN | three days later | +23.96% | final price |
| MDLN | three days earlier | +0.90% | final price |
| MDLN | five days earlier | +4.92% | final price |
| MMM | that day | +2.34% | final price |
| MMM | the next day | +1.58% | final price |
| MMM | two days later | +11.32% | final price |
| MMM | three days later | +7.71% | final price |
| MMM | three days earlier | -0.89% | final price |
| MMM | five days earlier | -0.88% | final price |
| NVCR | that day | +0.42% | final price |
| NVCR | the next day | +2.40% | final price |
| NVCR | two days later | +11.19% | final price |
| NVCR | three days later | +3.16% | final price |
| NVCR | three days earlier | +7.65% | final price |
| NVCR | five days earlier | +9.63% | final price |
| QQQ | that day | -1.30% | final price |
| QQQ | the next day | -0.76% | final price |
| QQQ | two days later | +0.17% | final price |
| QQQ | three days later | -5.59% | final price |
| QQQ | three days earlier | +5.08% | final price |
| QQQ | five days earlier | +3.12% | final price |
| SYK | that day | +5.34% | final price |
| SYK | the next day | +6.53% | final price |
| SYK | two days later | +16.59% | final price |
| SYK | three days later | +14.97% | final price |
| SYK | three days earlier | +4.38% | final price |
| SYK | five days earlier | +5.10% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days later | +0.17% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. Thomas H. Kean Jr sold Stryker (SYK), worth $1,001 - $15,000 on 30 Sep 2026. That is 32 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 37 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 51 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 9 Sep 2026. That is 53 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 4 Sep 2026. That is 58 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (held by a dependent child), worth $1,001 - $15,000 on 3 Sep 2026. That is 59 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“NovoCure Limited 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2026-10-31” scores 12 out of 100. The score uses 1 sources.